Kidney Disease

The treatment of CAD in patients with type 2 diabetes may need to be more aggressive compared with those without diabetes to reduce the risk for MI and other complications, according to an American Heart Association scientific statement published in Circulation.

The kidney care community must change the way dialysis is provided to most patients with ESKD before the next pandemic arrives, two nephrologists wrote in a recently published editorial.

SCOTTSDALE, Arizona — More research is needed on the value of anticoagulation for patients with late-stage chronic kidney disease with atrial fibrillation who are on dialysis in efforts to prevent stroke, according to a presentation here.

After addressing disparities regarding which patient populations are most likely to develop chronic kidney disease, a speaker at the virtual National Kidney Foundation Spring Clinical Meetings touched on a strategy to mitigate such disparities, an effort she deemed “a great success.”

Having a broader assessment of kidney health will improve diagnostic accuracy and provide noninvasive methods to monitor changes without repeated biopsies, according to a speaker at the virtual National Kidney Foundation Spring Clinical Meetings.

SCOTTSDALE, Arizona — There is an important unmet need for multidisciplinary care models to utilize the novel antihyperglycemic agents to lower cardiorenal outcomes in patients, according to an expert at the Cardio Renal Metabolic Conference.

The American Kidney Fund’s Clinical Scientist in Nephrology Fellowship program received a grant of $100,000 from the Hearst Foundation.

“We have proven, for the first time in a prospective study, that the urinary proteomic-based analysis CKD273 works as a predictor for future risk for progression in kidney disease, both for increase in albuminuria as well as for loss of renal function,” Peter Rossing, MD, head of diabetes complications research at the Steno Diabetes Center in Gentofte, Denmark, told Healio. “Secondly, we tried to see if we could mitigate this risk with spironolactone. That was not possible to show, maybe because the study was smaller than initially planned or maybe because it just does not work. However, as we begin to see renal benefits in studies with SGLT2 inhibitors and GLP-1 receptor agonists, it would be obvious to test some of these compounds in future studies, and we are trying to set that up.”

SCOTTSDALE, Arizona — Nephrologists and primary care clinicians should work together to help detect, diagnose and treat patients with chronic kidney disease, according to an expert at the Southwest Nephrology Conference.

Kerry Willis, PhD, was presented with the Garabed Eknoyan Award at the virtual National Kidney Foundation Spring Clinical Meetings. Willis serves as chief scientific officer for the organization.